オハイオにおける悪性黒色腫の臨床試験
オハイオ内の拠点で、悪性黒色腫に関する40件の研究が参加者を募集しています。
オハイオ内の都市
- Columbus21件の研究
- Cincinnati17件の研究
- Cleveland13件の研究
- Akron8件の研究
- Toledo8件の研究
- Dayton7件の研究
- Newark3件の研究
- Findlay3件の研究
- Parma3件の研究
- Youngstown3件の研究
公式研究テキスト（英語）
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Oncology Hematology Care Clinical Trials, Cincinnati
- Seidman Cancer Center, Cleveland
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06246916BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Miami Valley Hospital South, Centerville
- Premier Blood and Cancer Center, Dayton
- Miami Valley Hospital North, Dayton
- 他2件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05136196DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
被験者募集中観察研究
18歳〜130歳 · 全性別 · 2026/09/25更新 · NCT07124000Pan-tumor MRD Study
- Gabrail Cancer Center, Canton
- Taylor Cancer Research Center, Maumee
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Good Samaritan Hospital - Cincinnati, Cincinnati
- 他5件
被験者募集中第3相
75歳以上 · 全性別 · 2026/09/24更新 · NCT07068074Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Oncology Hematology Care, Cincinnati
- Ohio State University, Columbus
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT05727904A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
被験者募集中第2相
25歳以下 · 全性別 · 2026/09/24更新 · NCT07621614Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
- Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT06529822A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- 他56件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- University of Cincinnati Medical Center, Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT07287917A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/02更新 · NCT04913285A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Cleveland Clinic Taussig Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- 他44件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/09/02更新 · NCT05334069Project: Every Child for Younger Patients With Cancer
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies and Childrens Hospital, Cleveland
- 他5件
被験者募集中観察研究
25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- University of Cincinnati Cancer Center, Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/14更新 · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳〜99歳 · 全性別 · 2026/07/13更新 · NCT04697576Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05588453A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
- University of Cincinnati, Cincinnati
被験者募集中第1/2相
18歳〜70歳 · 全性別 · 2026/06/11更新 · NCT05361174Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- University of Cincinnati Cancer Center, Cincinnati
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/08更新 · NCT03947385Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Christ Hospital Cancer Center, Cincinnati
- Taylor Cancer Research Center, Maumee
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/13更新 · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Cole Eye Institute-9500 Euclid Ave, Cleveland
- Ohio State Eye and Ear Institute, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/05/06更新 · NCT07015190A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- The Ohio State University, Columbus
被験者募集中第2/3相
全年齢 · 全性別 · 2026/04/02更新 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Indu and Raj Soin Medical Center, Beavercreek
- Strecker Cancer Center-Belpre, Belpre
- Dayton Physician LLC - Englewood, Dayton
- 他9件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳〜99歳 · 全性別 · 2026/03/10更新 · NCT06223659Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/03/09更新 · NCT04792463Promoting Immunotherapy Efficacy With Low-Dose Liver RT
- University of Cincinnati Medical Center, Cincinnati
被験者募集中
18歳以上 · 全性別 · 2026/02/27更新 · NCT07225036Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/25更新 · NCT05549297A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/02/17更新 · NCT04567706Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Ohio State University Wexner Medical Center, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2025/12/17更新 · NCT03567889A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 138, Canton
- Research Site 113, Cincinnati
- Research Site 131, Dayton
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/10/29更新 · NCT06249048SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Gabrail Cancer Center Research, Canton
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/05/18更新 · NCT05970497Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- University Hospitals Avon Health Center, Avon
- Miami Valley Hospital South, Centerville
- University Hospitals Geauga Medical Center, Chardon
- 他6件
被験者募集中
18歳以上 · 全性別 · 2024/11/27更新 · NCT03860883A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2024/11/25更新 · NCT05824975ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。